Inhibition of tumor cell migration by LD22-4, an N-terminal fragment of 24-kDa FGF2, is mediated by neuropilin 1

Cancer Research

Volumn 73, Issue 11, 2013, Pages 3316-3325

  Zhang, Ling ^a   Parry, Graham C ^b   Levin, Eugene G ^a,b  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b Motility Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; FIBROBLAST GROWTH FACTOR 2; HEPARAN SULFATE; HEPARIN; LD 22 4; MEMBRANE RECEPTOR; NEUROPILIN 1; RECOMBINANT GROWTH FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CELL GROWTH PROCESSES; CELL MOVEMENT; FEMALE; FIBROBLAST GROWTH FACTOR 2; GLIOMA; HEK293 CELLS; HEPARIN; HUMANS; MICE; MICE, NUDE; NEUROPILIN-1; PEPTIDE FRAGMENTS; PROTEIN BINDING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878617011     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3015     Document Type: Article

References (43)

1. Ding L, Donate F, Parry GC, Guan X, Maher P, Levin EG. Inhibition of cell migration and angiogenesis by the amino-terminal fragment of 24kD basic fibroblast growth factor. J Biol Chem 2002;277:3-61.
2. Levin EG, Sikora L, Ding L, Rao SP, Sriramarao P. Suppression of tumor growth and angiogenesis in vivo by a truncated form of 24-kd fibroblast growth factor (FGF)-2. Am J Pathol 2004;164:3-90.
3. Lin AH, Eliceiri BP, Levin EG. FAK mediates the inhibition of glioma cell migration by truncated 24 kDa FGF-2. BiochemBiophys Res Commun 2009;382:3-7.
4. Levin EG. Cancer therapy through control of cell migration. Curr Cancer Drug Targets 2005;5:505-18.
5. Piotrowicz RS, Maher PA, Levin EG. Dual activities of 22-24 kDA basic fibroblast growth factor: inhibition of migration and stimulation of proliferation. J Cell Physiol 1999;178:3-53.
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:3-76.
7. Pellet-many C, Frankel P, Jia H, Zachary I. Neuropilins: structure, function and role in disease. Biochem J 2008;411:3-26.
8. Zachary IC, Frankel P, Evans IM, Pellet-many C. The role of neuropilins in cell signaling. Biochem Soc Trans 2009;037:3-8.
9. Pan Q, Chathery Y, Wu Y, Rathore N, Tong RK, Peale F, et al. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem 2007;282:3-56.
10. Pellet-many C, Frankel P, Evans IM, Jünemann-Ramírez M, Zachary I. Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migration and signalling via p130Cas. Biochem J 2011; 435:3-618.
11. Bagnard D, Vaillant C, Khuth ST, Dufay N, Lohrum M, Puschel AW, et al. Semaphorin 3A-vascular endothelial growth factor-165 balance mediates migration and apoptosis of neural progenitor cells by the recruitment of shared receptor. J Neurosci 2001;21:3-41.
12. Jia H, Cheng L, Tickner M, Bagherzadeh A, Selwood D, Zachary I. Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity. Br J Cancer 2010;102:541-52.
13. Favier B, Alam A, Barron P, Bonnin J, Laboudie P, Fons P, et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 2006;108:3-50.
14. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor Flt-1. J Biol Chem 2000;275:3-5.
15. Gu C, Limberg BJ, Whitaker GB, Perman B, Leahy DJ, Rosenbaum JS, et al. Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J Biol Chem 2002;277:3-76.
16. Prahst C, Héroult M, Lanahan AA, Uziel N, Kessler O, Shraga-Heled N, et al. Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. J Biol Chem 2008;283:25110-4.
17. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007;11:53-67.
18. Ball SG, Bayley C, Shuttleworth CA, Kielty CM. Neuropilin-1 regulates platelet-derived growth factor receptor signalling in mesenchymal stem cells. Biochem J 2010;427:3-40.
19. Evans IM, Yamaji M, Britton G, Pellet-many C, Lockie C, Zachary IC, et al. Neuropilin-1 signaling through p130Cas tyrosine phosphorylation is essential for growth factor-dependent migration of glioma and endothelial cells. Mol Cell Biol 2011;31:3-85.
20. Hu B, Guo P, Bar-Joseph I, Imanishi Y, Jarzynka MJ, Bogler O, et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF//SF autocrine pathway. Oncogene 2007; 26:3-86.
21. Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J BiolChem 2002;277:3-25.
22. West DC, Rees CG, Duchesne L, Patey SJ, Terry CJ, Turnbull JE, et al. Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J Biol Chem 2005;280:3-64.
23. Bagri A, Tessier-Lavigne M, Watts RJ. Neuropilins in tumor biology. Clin Cancer Res 2009;156:1860-4.
24. Ellis LM. The role of neuropilins in cancer. Mol Cancer Ther 2006;5: 3-107.
25. Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont AM, et al. Small molecules and targeted therapies in distant metastatic disease. Ann Oncol 2009;20 Suppl 6:vi35-vi40.
26. Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, Chung YC, et al. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res 2007;13:3-68.
27. Shintani Y, Takashima S, Asano Y, Kato H, Liao Y, Yamazaki S, et al. Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. EMBO J 2006;25:3-55.
28. Jones KS, Lambert S, Bouttier M, Bénit L, Ruscetti FW, Hermine O, et al. Molecular aspects of HTLV-1 entry: functional domains of the HTLV-1 surface subunit (SU) and their relationships to the entry receptors. Viruses 2011;3:3-810.
29. Chiodelli P, Mitola S, Ravelli C, Oreste P, Rusnati M, Presta M. Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin. Arterio Thromb Vasc Biol 2011;31:e116-27.
30. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A 2009;106:3-62.
31. von Wronski MA, Raju N, Pillai R, Bogdan NJ, Marinelli ER, Nanjappan P, et al. Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor. J Biol Chem 2006;281:3-10.
32. Vander Kooi CW, Jusino MA, Perman B, Neau DB, Bellamy HD, Leahy DJ. Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci U S A 2007;104:3-7.
33. Starzec A, Ladam P, Vassy R, Badache S, Bouchemal N, Navaza A, et al. Structure function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF165 binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides 2007;28:2397-402.
34. Cébe Suarez S, Pieren M, Cariolato L, Arn S, Hoffmann U, Bogucki A, et al. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci 2006;63:3-77.
35. Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arterio Thromb Vasc Biol 1989;9: 3-32.
36. Breitwieser GE. G protein coupled receptor oligomerization. Circ Res 2004;94:3-27.
37. Davis MM, Krogsgaard M, Huppa JB, Sumen C, Purbhoo MA, Irvine DJ, et al. Dynamics of cell surface molecules during T cell recognition. Annu Rev Biochem 2003;72:3-42.
38. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002;110:669-72.
39. Roth L, Nasarre C, rrig-Grosch S, Aunis D, Cremel G, Hubert P, et al. Transmembrane domain interactions control biological functions of neuropilin-1. Mol Biol Cell 2008;19:3-54.
40. Nasarre C, Roth M, Jacob L, Roth L, Koncina E, Thien A, et al. Peptidebased interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo. Oncogene 2010;29:3-92.
41. Valdembri D, Caswell P, Anderson K, Schwarz J, König I, et al. Neuropilin-1/GIPC1 signaling regulates a5b1 integrin traffic and function in endothelial cells. Plos Biol 2009;7:25.
42. Murga M, Fernandez-Capetillo O, Tosato G. Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood 2005;105:1992-9.
43. Wang L, Mukhopadhyay D, Xu X. C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. FASEB J 2006;20:3-5.